LUNG SQUAMOUS CELL CARCINOMA
Clinical trials for LUNG SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new LUNG SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for LUNG SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets Hard-to-Treat cancers with genetic weakness
Disease control Recruiting nowThis study tests an experimental drug called TER-2013 in people with advanced solid tumors (like breast, endometrial, or lung cancer) that have specific changes in the AKT/PI3K/PTEN pathway. The goal is to see if the drug is safe, how the body processes it, and whether it can shr…
Matched conditions: LUNG SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Terremoto Biosciences Inc. • Aim: Disease control
Last updated Jun 16, 2026 23:08 UTC
-
New injection shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study tests a new drug called JMT106 in 200 adults with advanced solid tumors (like lung or liver cancer) who have run out of standard options. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. Participants receive the…
Matched conditions: LUNG SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Shanghai JMT-Bio Inc. • Aim: Disease control
Last updated Jun 16, 2026 12:55 UTC
-
New drug cocktail takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis study tests an experimental drug called AZD5335, alone or with other cancer treatments, in people with advanced ovarian, lung, or endometrial cancers. The goal is to see if it is safe and shrinks tumors. About 506 adults will take part, and the drug is given by IV.
Matched conditions: LUNG SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 15, 2026 19:08 UTC
-
Radiation boost may supercharge lung cancer therapy
Disease control Recruiting nowThis study tests whether adding low-dose radiation to a combination of immunotherapy (sintilimab) and chemotherapy can shrink tumors better than immunotherapy and chemo alone in people with advanced squamous cell lung cancer. About 114 participants will be randomly assigned to on…
Matched conditions: LUNG SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Sichuan University • Aim: Disease control
Last updated Jun 15, 2026 18:57 UTC